BELLUS Health (TSE:BLU) Now Covered by BTIG Research

ETFS

Investment analysts at BTIG Research began coverage on shares of BELLUS Health (TSE:BLU) in a report released on Monday, TipRanks reports. The brokerage set a “buy” rating and a C$18.00 price target on the stock. BTIG Research’s price target suggests a potential upside of 70.94% from the stock’s current price.

Other equities research analysts have also issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a C$14.00 price target on shares of BELLUS Health in a report on Friday, November 12th. Cowen reaffirmed a “buy” rating and set a C$15.00 price target on shares of BELLUS Health in a report on Monday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, BELLUS Health presently has an average rating of “Buy” and a consensus target price of C$13.75.

Shares of TSE:BLU opened at C$10.53 on Monday. The firm has a 50 day moving average of C$7.97 and a 200-day moving average of C$5.87. The stock has a market capitalization of C$825.06 million and a PE ratio of -9.69. The company has a current ratio of 3.42, a quick ratio of 3.21 and a debt-to-equity ratio of 0.41. BELLUS Health has a 12 month low of C$3.32 and a 12 month high of C$12.59.

BELLUS Health (TSE:BLU) last issued its earnings results on Wednesday, November 10th. The company reported C($0.37) EPS for the quarter, missing the consensus estimate of C($0.30) by C($0.07). The firm had revenue of C$0.01 million for the quarter, compared to the consensus estimate of C$0.01 million. On average, research analysts predict that BELLUS Health will post -1.11 EPS for the current fiscal year.

About BELLUS Health

BELLUS Health Inc, a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus.

Featured Article: What is the Shanghai Stock Exchange Composite Index?

Analyst Recommendations for BELLUS Health (TSE:BLU)

Want More Great Investing Ideas?

Products You May Like